“The company expects preliminary revenue for the third quarter ended September 30, 2025, to be approximately $17 million. In connection with the company’s credit agreement with OrbiMed, the company has secured a waiver for the third quarter 2025 trailing 12-month net revenue covenant, and is in discussions with OrbiMed to redefine future covenants. While the outcome of those discussions is yet to be determined, the parties remain focused on maintaining a constructive agreement. The company is assessing annual guidance and will provide an update on the company’s third quarter earnings call scheduled for November 6,” Avita Medical (RCEL) stated.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
- Avita Medical CEO Corbett leaving, Chairman Vance appointed Interim CEO
- Avita Medical downgraded to Hold from Buy at Lake Street
- Avita Medical Appoints Cary Vance as Interim CEO
- Avita Medical to be eligible for NTAP reimbursement from CMS for RECELL
- Avita Medical says data shows hospital stay reduction with RCELL System